Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depigoid Birch 5000 placebo-controlled long-term study in birch pollen allergic rhinitis
2012-000414-11Phase 3Completed
- Sponsor
- LETI Pharma
- Start
- May 2012
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3 trial of depigoid birch in seasonal allergic rhinitis (SAR), allergic rhinoconjunctivitis (ARC), birch pollen allergy and 1 more (2 arms), sponsored by LETI Pharma. Primary endpoints: Mean integrated combined Symptom and Rescue Medication score and Difference in SMS + RMS in eDiary for year 3. Started May 2012; status: completed.
02
Drugs
depigoid birch
03
Conditions
seasonal allergic rhinitis (SAR)allergic rhinoconjunctivitis (ARC)birch pollen allergyasthma
Beyond the preview
Go deeper on 2012-000414-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000414-11.